Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03626623 · ClinicalTrials.gov registry record · NA
Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care
A NA study, sponsored by Integra LifeSciences Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT03626623 is a NA study that was terminated before completion, run by Integra LifeSciences Corporation. The registered enrollment target is 15 participants.
The verdict
NCT03626623, a NA study, was terminated before completion, sponsored by Integra LifeSciences Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a two-armed randomized controlled trial (RCT) primarily aimed at determining if application of Cytal Wound Matrix 1-Layer intervention to diabetic foot ulcers shows improved wound closure rates when compared to standard care intervention.
Interventions
- OTHER Standard of Care (SOC)
- DEVICE Cytal Wound Matrix 1-Layer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2020-02-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03626623
The ClinicalTrials.gov registry entry for NCT03626623 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Integra LifeSciences Corporation, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care (SOC) is the first listed.
NCT03626623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03626623 about?
NCT03626623 is a clinical study titled "Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care". This is a two-armed randomized controlled trial (RCT) primarily aimed at determining if application of Cytal Wound Matrix 1-Layer intervention to diabetic foot ulcers shows improved wound closure rates when compared to standard care intervention.
What is the current status of trial NCT03626623?
This trial is currently terminated. It is a NA study. The enrollment target is 15 participants. The study started on 2019-05-21. Estimated completion is 2020-02-18.
What interventions are being tested in trial NCT03626623?
The interventions under investigation include: Standard of Care (SOC) (OTHER), Cytal Wound Matrix 1-Layer (DEVICE).
Who is sponsoring clinical trial NCT03626623?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.